Clinical Trials Logo

Filter by:
NCT ID: NCT05744193 Not yet recruiting - Clinical trials for VLBW - Very Low Birth Weight Infant

Feeding Study in VLBW Premature Infants

Start date: May 15, 2023
Phase: N/A
Study type: Interventional

A multi-center, single-blind, randomized, controlled, parallel-designed, prospective trial to compare growth between preterm infants fed one of three study human milk fortifiers added to human milk

NCT ID: NCT05743699 Not yet recruiting - Substance Use Clinical Trials

Adaptation and Evaluation of Bright Horizons

Start date: July 2024
Phase: N/A
Study type: Interventional

This study will test if a program called 'Bright Horizons' is effective at reducing binge substance use among adolescents. Bright Horizons is a culturally adapted intervention developed and tested through a partnership between The White Mountain Apache Tribe and Johns Hopkins University. Bright Horizons is a brief intervention that teaches emotion regulation, coping skills, and problem solving. The intervention also uses goal setting to reduce alcohol and other substance use and to connect to individuals with treatment.

NCT ID: NCT05741164 Not yet recruiting - Clinical trials for Anatomic Stage III Breast Cancer AJCC v8

Propranolol and Pembrolizumab for Tumor Re-sensitization and Treatment of Patients With Checkpoint Inhibitor Refractory Metastatic or Unresectable Triple Negative Breast Cancer

Start date: August 30, 2024
Phase: Phase 2
Study type: Interventional

This phase II trial tests how well propranolol and pembrolizumab work to cause tumor re-sensitization and therefore treatment in patients with triple negative breast cancer that has not responded to previous checkpoint inhibitor therapy (refractory), cannot be removed by surgery (unresectable) or has spread from where it first started (primary site) to other places in the body (metastatic). Propranolol is a drug that is classified as a beta-blocker. Beta-blockers affect the heart and circulation. Beta-blockers, like propranolol, may help to counteract effects of certain stress hormones produced by the body during cancer treatment and may increase the effectiveness of the pembrolizumab. Pembrolizumab is a drug that is classified as an immune checkpoint inhibitor. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Propranolol may be able to re-sensitize the cells of the immune system to respond to the checkpoint inhibitor pembrolizumab in patients with checkpoint inhibitor refractory metastatic or unresectable triple negative breast cancer.

NCT ID: NCT05741125 Not yet recruiting - Type 2 Diabetes Clinical Trials

Improving Appetite Self-Regulation in African American Adults With Type 2 Diabetes

Start date: January 9, 2024
Phase: N/A
Study type: Interventional

The purpose of this 6-month randomized clinical trial is to examine the feasibility of recruitment, attendance, retention, program adherence, and satisfaction of a digital application designed, Centering Appetite to improve glucose scores (HbA1c) and binge eating in African American adults with type 2 diabetes. Intervention participants will receive type 2 diabetes education and web-based lessons on appetite self-regulation. Participants will also receive a Fitbit to monitor daily physical activity. The investigators will follow up with participants at six months.

NCT ID: NCT05736705 Not yet recruiting - Esophageal Neoplasm Clinical Trials

Monopolar and Bipolar in Esophageal ESD

Start date: March 31, 2024
Phase: N/A
Study type: Interventional

The objective of this study is to prospectively document the efficacy and clinical outcomes of Endoscopic Submucosal Dissection procedure that utilize either a novel Bipolar-Current ESD device or the standard monopolar electrocautery knife.

NCT ID: NCT05736367 Not yet recruiting - Breast Cancer Clinical Trials

Investigating the Metabolic Pathways in Hormone Receptor Positive/HER2 Negative Breast Cancer

Start date: April 15, 2024
Phase: N/A
Study type: Interventional

To analyze the metabolic activity of Hormone Receptor Positive (HR+)/Her 2 Negative (Her2-) Breast cancer.

NCT ID: NCT05736198 Not yet recruiting - Difficult Airway Clinical Trials

Comparison of Two Sedation Regimens for Awake Fiberoptic Intubation

Start date: June 12, 2023
Phase:
Study type: Observational

The purpose of this study is to examine the effects of different sedation drugs used for the awake fiberoptic intubation procedure. Benzodiazapines and narcotics (such as midazolam and fentanyl) are standard drugs used for sedation during awake fiberoptic intubation. Dexmedetomidine, midazolam, and fentanyl are approved by the Food and Drug Administration (FDA) procedural sedation. These drugs might be given to the patient regardless of their participation in the study. In addition to midazolam and fentanyl study subjects will also receive either dexmedetomidine or a placebo (a salt solution that contains no drug). It is believed that dexmedetomidine will not slow down breathing as much as the combination of the valium-like drug and narcotic. In our study, we are trying to determine if this is the best drug for sedation during an awake fiberoptic procedure.

NCT ID: NCT05735314 Not yet recruiting - Anemia Clinical Trials

A New Combination of Evidence-Based Interventions to Improve Primary Care Diagnostic Safety and Efficiency

Start date: May 15, 2023
Phase: N/A
Study type: Interventional

The purpose of this study is to measure the evidence-based intervention's (EBIs) impact on patient safety and efficiency, to assess the EBIs implementation by measuring acceptability, appropriateness, cost, fidelity, penetration, and sustainability and to identify the facilitators and barriers that influence the degree of implementation of these EBIs.

NCT ID: NCT05735158 Not yet recruiting - Clinical trials for Autosomal Recessive Ichthyosis

Topical KB105 for the Treatment of TGM1-deficient Autosomal Recessive Congenital Ichthyosis (ARCI)

Start date: March 2023
Phase: Phase 2
Study type: Interventional

KB105-02 is an intrasubject randomized, placebo-controlled, double-blind study to evaluate the safety and efficacy of KB105 in children and adults with autosomal recessive congenital ichthyosis (ARCI).

NCT ID: NCT05734014 Not yet recruiting - Clinical trials for Violence in Adolescence

Strengthening Healthy Relationships Among Apsaalooke Youth

Start date: May 1, 2023
Phase: N/A
Study type: Interventional

This pilot project proposes to build upon these cultural strengths, including the clan system, to test the feasibility of a translational research intervention to promote healthy relationships and prevent dating violence among Apsáalooke youth. Community Advisory Board members identified 5th grade as an important age to establish healthy dating norms. The feasibility study includes a one-group pre/post intervention that includes 10-hour long sessions with youth to promote healthy relationship knowledge, volition, and communication skills. Elders and near-peer (young adults) will assist during these sessions sharing advice and serving as role models for youth. In addition, to promote the connectedness between youth and their community, there are 3 monthly clan feeds.